Main Article Content
In current scenario, the investigational studies in pathology fields focus on those microbiotas which can produce
sever disorders and also terminate the microbiota colonies that cause or which altered and arise with some diseasecausing
agents. Fecal microbiota transplantation (FMT) may alter the acceptors gut microbiota and maintain the
composition in normal range, which helps to give beneficial pharmacological effects in gastrointestinal tract
(GIT) related disease as well as, extra-GIT disorders. Alteration in microbiomes have given appropriate clinical
perceptions in both gut and oral disorders. FMT re-established miscellaneous bacterial profile to GIT. The study
was focused on the evaluation of efficacy of this method to treat various infections arises with Clostridium difficile
bacteria. From the various studies, it may be hypothesized that the FMT reflects that it has potency to treat the
C. difficile infections and achieved success rate in between 80 and 100%. Fecal microbiota can be transplant by
both either antegrade or retrograde routes. The history of FMT belongs to the 4th century and comes in enforcement
in 2013 after approving by the USFDA.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.